0001062993-16-012532.txt : 20161129
0001062993-16-012532.hdr.sgml : 20161129
20161129171511
ACCESSION NUMBER: 0001062993-16-012532
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161128
FILED AS OF DATE: 20161129
DATE AS OF CHANGE: 20161129
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP
CENTRAL INDEX KEY: 0000875622
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 113054851
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 WILBUR ST
CITY: LYNBROOK
STATE: NY
ZIP: 11563
BUSINESS PHONE: 5165937000
MAIL ADDRESS:
STREET 1: 35 WILBUR STREET
CITY: LYNBROOK
STATE: NY
ZIP: 11563
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wegman Thomas
CENTRAL INDEX KEY: 0001355189
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34236
FILM NUMBER: 162023482
MAIL ADDRESS:
STREET 1: 1764 BRIAR PLACE
CITY: MERRICK
STATE: NY
ZIP: 11566
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2016-11-28
0000875622
BIOSPECIFICS TECHNOLOGIES CORP
BSTC
0001355189
Wegman Thomas
C/O BIOSPECIFICS TECHNOLOGIES CORP.
35 WILBUR STREET
LYNBROOK
NY
11563
1
1
1
0
President
Common Stock, $.001 par value
2016-11-28
4
S
0
11055
48.0369
D
964824
D
Common Stock, $.001 par value
2016-11-29
4
S
0
8945
48.3161
D
955879
D
The selling price of $48.0369 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $47.50 to $49.40. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The selling price of $48.3161 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $48.25 to $48.77. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
/s/ Carl A. Valenstein, attorney-in-fact for Thomas Wegman
2016-11-29